The Group

Web 3.0 Era Begins, Lion Group Holdings (LGHL.US) Gets a Head Start

Retrieved on: 
Monday, November 7, 2022
DLT, Research, Broker, Orangi Pilot Project, Growth, The Group, Policy, Metap, Finance, Lion Group, NFT, Commerce, Mecha, Non-fungible token, CEO, TRS, LGHL, Statement, Wilson, Lion, Distributed ledger, The Statement, NASDAQ, Semantic Web, UGC, Development, Partnership, SPAC, CFD, Unreal Engine, Cryptocurrency, Metaverse

LGHL is currently wrapping up phase one development of its metaverse project, Lion World.

Key Points: 
  • LGHL is currently wrapping up phase one development of its metaverse project, Lion World.
  • Recently, the Financial Secretary of Hong Kong released a "Policy Statement on the Development of Virtual Assets ("VA") in Hong Kong" ("the Statement").
  • The statement also announced a number of pilot projects which include non-fungible token (NFT) issuance, green bond tokenization and e-HKD.
  • Development of Lion World began in 2021 as an extension of its "Metaverse AI Tool" development partnership with Dawa Technology.

SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company

Retrieved on: 
Friday, November 4, 2022
Technology, Company, SM03, Pemphigus, Research, Central China, Therapy, Growth, Asthma, The Company, Non-Hodgkin lymphoma, State Council, NHL, Damage-associated molecular pattern, Lupus, Twelfth, Sino Biopharmaceutical Limited, SLE, Barakat Pharmaceutical Group, RA, Rheumatoid arthritis, The Group, Thirteenth, WANG, CD22, Autoimmune disease, B-cell lymphoma, Mab, Degenerative disease, Pharmaceutical industry, Group

Mr. Shanchun WANG, served as the executive director of Sino Biopharmaceutical Limited (stock code: 1177) and the president of Chia Tai - Tianqing Pharmaceutical Group Co. Ltd., joined SinoMab lately as the President (China) of the Company.

Key Points: 
  • Mr. Shanchun WANG, served as the executive director of Sino Biopharmaceutical Limited (stock code: 1177) and the president of Chia Tai - Tianqing Pharmaceutical Group Co. Ltd., joined SinoMab lately as the President (China) of the Company.
  • Mr. Shanchun WANG has rich experience and practical achievements in corporate strategic management, organizational management, innovation research and development and product commercialization.
  • Dr. Shui On LEUNG said that: "It is a great pleasure to have Mr. Shanchun WANG joining the Company.
  • Pursuant to the subscription agreement, Mr. Shanchun WANG conditionally agreed to subscribe for and the Company conditionally agreed to allot and issue 14,340,000 subscription shares.

Kidsland Appoints Zhong Mei as Co-Chief Executive Officer

Retrieved on: 
Monday, October 31, 2022
Board, Knowledge, CEO, Leadership, The Group, Group, Company, The Company, Growth, Industry, FAO Schwarz, Holding company, Management, Mainland China

HONG KONG, Oct 31, 2022 - (ACN Newswire) - Kidsland International Holdings Limited ("Kidsland" or the "Company", together with its subsidiaries, the "Group", stock code: 2122), the largest toy retailer and distributor in Mainland China, is pleased to announce the appointment of Ms. Zhong Mei ("Ms. Zhong"), currently an Executive Director of the Company and the Managing Director of Kidsland in Mainland China, as Co-Chief Executive Officer of the Company, effective 1 November 2022.

Key Points: 
  • HONG KONG, Oct 31, 2022 - (ACN Newswire) - Kidsland International Holdings Limited ("Kidsland" or the "Company", together with its subsidiaries, the "Group", stock code: 2122), the largest toy retailer and distributor in Mainland China, is pleased to announce the appointment of Ms. Zhong Mei ("Ms. Zhong"), currently an Executive Director of the Company and the Managing Director of Kidsland in Mainland China, as Co-Chief Executive Officer of the Company, effective 1 November 2022.
  • She was appointed as an Executive Director in 2017 and currently heads up the Group's Mainland China operations as Managing Director.
  • Mr. Lee Ching Yiu, Chairman and CEO of Kidsland, said, "We are delighted to announce the appointment of Ms. Zhong as the new Co-CEO of Kidsland.
  • Currently, its self-operated offline retail system includes kidsland stores, LEGO Certified Stores, FAO Schwarz flagship store and kkplus kidsland.

Acceptance Of The Application For Clinical Trial Of Recbio Novel Adjuvanted Recombinant Quadrivalent HPV Vaccine

Retrieved on: 
Friday, October 28, 2022
People, R, Recovered-memory therapy, Article, Company, Clinical trial, The Group, Achievement, Group, Center, Terminology, Vaccine, Shingles, National Medical Products Administration, Policy by press release, Stock exchange, TB, Cervical cancer, Republic, Center for Drug Evaluation and Research, HPV, Research, COVID-19, Administration, Protein engineering, RNA transfection, The Company, Vaccination, WHO, Health, Gardasil

Compared with three-shot of HPV vaccine Gardasil, the levels of HPV neutralizing antibodies induced by two-shot of REC604a were higher than those induced by three-shot of Gardasil.

Key Points: 
  • Compared with three-shot of HPV vaccine Gardasil, the levels of HPV neutralizing antibodies induced by two-shot of REC604a were higher than those induced by three-shot of Gardasil.
  • Founded in 2012, Jiangsu Recbio Technology Co., Ltd. (hereinafter referred to as Recbio or the Company; stock code: 02179.HK) is an innovative vaccine company driven by self-developed technologies.
  • We develop promising vaccine candidates constantly, taking advantage of the synergy between the novel adjuvant platform, optimized antigen designs, and immunological evaluation technologies.
  • Our core product REC603, a recombinant 9-valent HPV vaccine in Phase III clinical trial, shows great promise of becoming the first marketed domestic 9-valent HPV vaccine.

Mr. Chow Bok Hin Felix was appointed as the new director of ASTRI

Retrieved on: 
Monday, October 24, 2022
Metaverse, Trust, Company, The Group, Hong Kong Applied Science and Technology Research Institute, Corporation, Intelligence, Group, Growth, High, National Intellectual Property Rights Coordination Center, Family, Integrated circuit, Female gendering of AI technologies, Technology, IOT, State Intellectual Property Office (Croatia), Hong Kong residents, Industry, Ecosystem, ASTRI, Executive, Application-specific integrated circuit, Research, Financial Technologies Group, The Company, Government, System, Communication, Digital health, Strategic planning, GEM, IEEE Transactions on Computer-Aided Design of Integrated Circuits and Systems, Management, PRC

As of 2021/22, ASTRI has transferred almost 1,250 technologies to the industry and has been granted over 1,000 patents in the Mainland, the US, and other countries.

Key Points: 
  • As of 2021/22, ASTRI has transferred almost 1,250 technologies to the industry and has been granted over 1,000 patents in the Mainland, the US, and other countries.
  • Being the new director of ASTRI, Mr. Chow's role and position in Niche-Tech Semiconductor will not be changed.
  • Mr. Chow Bok Hin said, "I am very honoured to join the family of ASTRI.
  • As the new director of ASTRI, I will contribute to the electronic materials industry.

Sword Group: Results for the Third Quarter 2022

Retrieved on: 
Tuesday, October 25, 2022
Sword, Group, YTD, The Group, Network equipment

(2) including 6.5m of Revenue from Sword GRC, sold in April 2022.

Key Points: 
  • (2) including 6.5m of Revenue from Sword GRC, sold in April 2022.
  • The 12.8% profitability in Q3 2021 was due to the consolidation of Sword GRC.
  • Without this entity the 2022 profitability is similar to the 2021 profitability.
  • The Revenue of 6.5m from Sword GRC, sold in 2022, is included in YTD Revenue.

Jonas Arlebäck has been appointed as Group CFO of Go North Group AB (Publ)

Retrieved on: 
Wednesday, October 26, 2022
Management consulting, McKinsey & Company, FBA, Growth, PETS, Investment, Technology, Sport, Group, CEO, The Group, HH, Jonas, Management, Accenture, Amazon

GOTEBORG, Sweden, Oct. 26, 2022 /PRNewswire/ -- Jonas Arlebck has today been appointed Group CFO of Go North Group AB (Publ) ("Go North", or "The Group") and will take up his role from today, 26 October.

Key Points: 
  • GOTEBORG, Sweden, Oct. 26, 2022 /PRNewswire/ -- Jonas Arlebck has today been appointed Group CFO of Go North Group AB (Publ) ("Go North", or "The Group") and will take up his role from today, 26 October.
  • "To strengthen Go North's leadership team with Jonas Arlebck as the Group CFO is a big achievement and further strengthens the group's speedfully execution of its vision.
  • And the timing could not be better due to our upcoming fundraising", says Johan Hallenby, CEO/Founder of Go North.
  • Go North has been using HH&P Executive Search AB for the recruitment of Jonas Arlebck.

EQS-News: Go North Group AB (publ) completes new equity round

Retrieved on: 
Saturday, October 22, 2022
Go North, Financial Conduct Authority, ERP, FBA, RNS, PETS, Investment, Technology, Sport, Acquisition, KSEK, Group, The Group, NPS, News, United Kingdom, EBITDA, London, EU, London Stock Exchange, Security (finance), Online shopping, Amazon

Go North Group AB (Publ) announces its first reported profitable month, contributing a positive EBITDA of kSEK 451 in September 2022

Key Points: 
  • Go North Group AB (Publ) announces its first reported profitable month, contributing a positive EBITDA of kSEK 451 in September 2022
    Go North Group AB (publ) ("Go North" or "The Group") is delighted that in September, we proved that we could execute against our previously communicated strategy, by delivering the first reported profitable month, contributing a positive EBITDA of kSEK 451.
  • Despite increasing inflation and cost of living, the timing for Go North from a macroeconomic outlook comes with big potential.
  • In summary, whilst Go North remains a learning organization, we're very pleased with the progress of the month.
  • This information is information that Go North Group AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation.

ESR Group achieves outstanding results in 2022 GRESB Assessment in recognition of its exemplary ESG performance

Retrieved on: 
Monday, October 17, 2022
Benchmark, New, MSCI Hong Kong Index, Biophysical environment, Renewable energy, Principles for Responsible Investment, PRI, Growth, Socially responsible investing, EFront Alternative Investment Solutions, ESG, Solution, Sustainability, FTSE Global Equity Index Series, Global, Office, Stock exchange, Region, Green Star (Australia), Investment, REIT, AUM, SLL, ESR, Social, Motherboard, The Group, GDP, Group, United Nations, Financial management, Prosperity, Hang Seng Composite Index Series, Environment, Leadership, Film, Financial services, New economy

These results are a recognition of the Group's Environmental, Social and Governance ("ESG") leadership and commitment across business units.

Key Points: 
  • These results are a recognition of the Group's Environmental, Social and Governance ("ESG") leadership and commitment across business units.
  • We are proud to have achieved another year of outstanding scores and thank GRESB for the strong recognition of our excellent ESG performance.
  • The consistent recognition by international indices such as GRESB cements our position as an ESG leader in real estate.
  • Tang Boon Kang, ESR Group Head, Governance & Sustainability and Emma Larsson, ESR Group ESG Officer, said: "ESR has made great progress on our ESG efforts set out in our ESG 2025 Roadmap.

Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech

Retrieved on: 
Thursday, October 13, 2022
Vance DeGeneres, Neurodegeneration, Anti-inflammatory, Hospital, Inflammation, Invention, VISTA, DED, Agreement, Eye, Glaucoma, Trial of the century, Product, Company, Leber's hereditary optic neuropathy, LHON, The Group, Mitochondrion, Group, Board, Duane syndrome, Patent, Oxidative stress, FDA, TRIPS Agreement, AMD, Pharmaceutical industry, Ophthalmology, SkQ, Dermatology

Mitotech S.A. is a clinical-stage Luxembourg-based biotechnology company developing novel drugs for the treatment of predominantly age-related disorders.

Key Points: 
  • Mitotech S.A. is a clinical-stage Luxembourg-based biotechnology company developing novel drugs for the treatment of predominantly age-related disorders.
  • The core technology behind Mitotech products is based on a novel class of small molecules - mitochondria targeting cardiolipin peroxidation inhibitors.
  • Company's lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases.
  • Additionally, glaucoma, Leber's Hereditary Optic Neuropathy (LHON), dry AMD, and uveitis programmes for SkQ1 ophthalmic solution are at pre-clinical stage.